CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −147 | $457.43 | $67K | 23,246 |
| 2025-10-02 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −3 | $457.64 | $1K | 23,243 |
| 2025-10-01 | SUPRAN BRYAN EVP, CLO and Secretary | Grant or award | +13,026 | 13,026 | ||
| 2025-10-01 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +3,108 | 53,229 | ||
| 2025-10-01 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +4,644 | 57,873 | ||
| 2025-10-01 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +3,860 | 60,081 | ||
| 2025-10-01 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +14,252 | 74,333 | ||
| 2025-10-01 | Tanguler Tolga EVP, Chief Commercial Officer | Grant or award | +2,851 | 28,843 | ||
| 2025-10-01 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award | +2,102 | 24,821 | ||
| 2025-10-01 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award | +2,851 | 27,672 | ||
| 2025-10-01 | Garg Pushkal EVP Chief R&D | Grant or award 10b5-1 | +3,108 | 23,329 | ||
| 2025-10-01 | Garg Pushkal EVP Chief R&D | Grant or award 10b5-1 | +2,851 | 26,180 | ||
| 2025-09-09 | Reitan Colleen F Director | Option exercise 10b5-1 | +18,000 | $100.65 | $1.8M | 18,775 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,645 | $457.44 | $752K | 17,130 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,888 | $458.86 | $866K | 15,242 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,403 | $459.73 | $645K | 13,839 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −473 | $460.71 | $218K | 13,366 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −2,290 | $461.92 | $1.1M | 11,076 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −1,652 | $463.00 | $765K | 9,424 |
| 2025-09-09 | Reitan Colleen F Director | Sale 10b5-1 | −799 | $464.36 | $371K | 8,625 |
Page 22 of 41 · 816 trades